3rd Dec 2015 08:09
LONDON (Alliance News) - NetScientific PLC said Thursday that its portfolio company ProAxis will present new data validating the use of its ProteaseTag immunoassay for the monitoring of patients with chronic obstructive pulmonary disease.
It will present the data at the British Thoracic Society Winter meeting in London.
The data shows that ProAxsis' product can effectively measure the level of active neutrophil elastase in the sputum of patients - as well as identifying a direct correlation between high levels of active neutrophil and exacerbations experience by the patients.
"These results validate the use of ProAxsis' technology in the management of COPD and represent a significant milestone for the company. ProAxsis continues to make strong progress and will continue to work with pharmaceutical and academic research groups focused on respiratory diseases to further assess the immunoassay. We look forward to working with ProAxsis to accelerate the development of this exciting technology that has the potential to improve the active monitoring of COPD and thus the lives of people all over the world," said Chief Executive Officer of NetScientific Francois Martelet in a statement.
Shares in NetScientific were untraded Thursday morning, shortly after market open. They last closed at 105.00 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific